Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.

Bayer

Status and phase: Completed; Phase 4

Conditions: Neoplastic CNS Lesions

Treatments: Drug: Dotarem; Drug: Gadovist® (Gadobutrol, BAY86-4875)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00764387

91780

312021 (Other Identifier)

2007-005693-31 (EudraCT Number)

Details and patient eligibility

About

Study to compare of two contrast agents in imaging brain lesions.

Enrollment: 166 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Known neoplastic CNS lesions

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

166 participants in 2 patient groups

Arm 1

Experimental group

Treatment:

Drug: Gadovist® (Gadobutrol, BAY86-4875)

Arm 2

Active Comparator group

Treatment:

Drug: Dotarem